These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 28984141)
1. Dabrafenib and trametinib in BRAFV600E mutated glioma. Brown NF; Carter T; Kitchen N; Mulholland P CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141 [TBL] [Abstract][Full Text] [Related]
2. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516 [TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib in patients with BRAF Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156 [TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
5. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156 [TBL] [Abstract][Full Text] [Related]
6. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
7. Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab. Thomas AA; Tucker SM; Nelson CJ; Nickerson JP; Durham SR; Homans AC Pediatr Blood Cancer; 2019 Jan; 66(1):e27465. PubMed ID: 30255633 [No Abstract] [Full Text] [Related]
8. Challenges of targeting Smith-Cohn M; Davidson C; Colman H; Cohen AL CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130 [No Abstract] [Full Text] [Related]
9. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer. Jeon Y; Park S; Lee SH; Kim TH; Kim SW; Ahn MJ; Jung HA; Chung JH Cancer Res Treat; 2024 Oct; 56(4):1270-1276. PubMed ID: 38453274 [TBL] [Abstract][Full Text] [Related]
10. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790 [TBL] [Abstract][Full Text] [Related]
11. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876 [No Abstract] [Full Text] [Related]
12. Dabrafenib Effective in Pediatric Glioma. Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673 [TBL] [Abstract][Full Text] [Related]
13. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
14. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Spain L; Julve M; Larkin J Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150 [TBL] [Abstract][Full Text] [Related]
15. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119 [TBL] [Abstract][Full Text] [Related]
16. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608 [TBL] [Abstract][Full Text] [Related]
17. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102 [TBL] [Abstract][Full Text] [Related]